Daniel Gesua Sive Salvadori Sells 71,157 Shares of Abbott Laboratories (ABT) Stock
Abbott Laboratories (NYSE:ABT) insider Daniel Gesua Sive Salvadori sold 71,157 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $55.00, for a total value of $3,913,635.00. Following the transaction, the insider now owns 144,955 shares in the company, valued at approximately $7,972,525. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Daniel Gesua Sive Salvadori also recently made the following trade(s):
- On Monday, October 23rd, Daniel Gesua Sive Salvadori sold 96,603 shares of Abbott Laboratories stock. The stock was sold at an average price of $56.21, for a total transaction of $5,430,054.63.
- On Tuesday, September 26th, Daniel Gesua Sive Salvadori sold 62,460 shares of Abbott Laboratories stock. The stock was sold at an average price of $52.95, for a total transaction of $3,307,257.00.
Abbott Laboratories (ABT) traded up $0.71 during trading on Thursday, hitting $55.54. The company had a trading volume of 6,820,428 shares, compared to its average volume of 6,677,073. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. The company has a market capitalization of $96,670.00, a PE ratio of 22.83, a price-to-earnings-growth ratio of 2.06 and a beta of 1.55. Abbott Laboratories has a fifty-two week low of $37.38 and a fifty-two week high of $56.69.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. The firm had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The company’s revenue was up 28.8% on a year-over-year basis. During the same period last year, the company earned $0.59 earnings per share. equities analysts predict that Abbott Laboratories will post 2.5 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Investors of record on Friday, October 13th were given a $0.265 dividend. The ex-dividend date was Thursday, October 12th. This represents a $1.06 dividend on an annualized basis and a yield of 1.91%. Abbott Laboratories’s payout ratio is 87.60%.
Several equities research analysts have recently issued reports on the stock. Cowen and Company restated a “buy” rating and issued a $55.00 price objective on shares of Abbott Laboratories in a research note on Thursday, August 17th. Stifel Nicolaus restated a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 21st. BidaskClub downgraded shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. BMO Capital Markets reaffirmed a “market perform” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $58.00 target price on shares of Abbott Laboratories in a research report on Thursday, August 3rd. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $56.81.
A number of hedge funds have recently made changes to their positions in ABT. Tributary Capital Management LLC acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth about $106,000. Heritage Trust Co grew its position in shares of Abbott Laboratories by 10.1% during the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock worth $106,000 after buying an additional 200 shares during the period. Winfield Associates Inc. grew its position in shares of Abbott Laboratories by 3.9% during the 2nd quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock worth $116,000 after buying an additional 89 shares during the period. Thompson Davis & CO. Inc. grew its position in shares of Abbott Laboratories by 17.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock worth $120,000 after buying an additional 370 shares during the period. Finally, V Wealth Management LLC acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth about $127,000. Hedge funds and other institutional investors own 70.64% of the company’s stock.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.